Atrium Therapeutics Q3 EPS $(0.25) Beats $(1.37) Estimate, Sales $15.321M Beat $666.667K Estimate
Benzinga Newsdesk 2 hours ago
NewsEarningsEarnings Beats
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(1.37) by 81.75 percent. This is a 80.31 percent increase over losses of $(1.27) per share
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(1.37) by 81.75 percent. This is a 80.31 percent increase over losses of $(1.27) per share from the same period last year. The company reported quarterly sales of $15.321 million which beat the analyst consensus estimate of $666.667 thousand by 2.20K percent. This is a 22.81 percent increase over sales of $12.475 million the same period last year.